In addition, compound 12 displayed no inhibition toward SIRT1–3.79 Hence, this molecule represents a new startingpoint for the development of dual SIRT5 and Bcl-2 inhibitors thatmay be relevant in cancer types where both proteins play a criticalrole. This evidence concerns the gene SIRT5 and cancer.